PCV155 IMPACT OF EXPANDING PHARMACY BENEFITS ON TREATMENT OF CONGESTIVE HEART FAILURE: THE CASE OF MEDICARE PART D  by Donohue, JM et al.
A342 Paris Abstracts
levels (6 studies) and greater proportions of patients achieving LDL goals (5 studies). 
CONCLUSIONS: Policy-driven programs that encourage wide-spread switching of 
statins without consideration of patient-speciﬁc circumstances may impact the delivery 
of patient care and treatment outcomes.
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OBJECTIVES: To determine the effect of an employer-sponsored pharmacist-provided 
medication therapy management program (MTMP) on clinical outcomes and social 
measures in patients with hypertension. METHODS: A prospective, intent-to-treat, 
pre-post longitudinal study. Patients were Lucas County employees and/ dependents 
with a diagnosis for hypertension. The face-to-face MTMP was provided by pharma-
cists from the Toledo Area Coalition of Independent Pharmacies at seven pharmacies. 
JNC-VII guidelines were used to design interventions and set patient goals. Interven-
tions were provided every six months. Information recorded included demographic 
information, clinical markers and social measures. Data was documented by pharma-
cists or pharmacy technicians using intake forms. Data was analyzed using SPSSv 16.0 
for two groups i.e. hypertension only (may have other comorbid conditions excluding 
diabetes) and hypertensive diabetics. Wilcoxon signed-rank test was used to compare 
2 time points and the Friedman test was to compare readings at baseline, six and 12 
months. RESULTS: Two hundred and twenty eight patients have enrolled in the 
program. For the hypertension only group, mean systolic blood pressure (SBP) 
improved from 133.73 o 17.36 to 130.86 o 16.49 (p  0.112). For uncontrolled 
hypertensive patients in this group, mean SBP improved from 152.54 o 11.80 to 
139.77 o 18.22 (p  0.000). Diastolic blood pressure improved from 99.330 to 91.50 
(p  0.049). For hypertensive diabetic patients mean SBP decreased from 135.64 o 
18.21 to 127.55 o 15.26 (p  0.003). Signiﬁcant decrease was also observed for 
hypertensive diabetic with uncontrolled blood pressure at baseline (146.26 o 13.55 to 
131.44 o 13.66 mmHg; p  0.000). Mean alcohol and caffeine consumption decreased 
non-signiﬁcantly for patients in both groups. CONCLUSIONS: Pharmacists interven-
tions assisted uncontrolled patients in reaching their goal BP reading, and for con-
trolled patients, helped in maintaining their level of control. Periodic monitoring by 
a pharmacist can assist patients in reaching their targeted goal and maintaining that 
value so as to prevent long-term complications and costs.
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OBJECTIVES: African American men have lower hypertension control rates and 
higher cardiovascular disease mortality rates than those of Caucasian males. We 
examined how a peer approach to hypertension management could improve blood 
pressure control for participants, mostly minority males. METHODS: This is a longi-
tudinal cohort study. Patients in the intervention group enrolled relatives or friends 
in the hypertension education program and attended as teams, the monthly education 
sessions. Patients in the control group followed standard of care. Blood pressure was 
taken by a nurse, at baseline and every 3 months, for up to 15 months. Other clinical 
and behavioral information was obtained from medical charts and surveys at baseline 
and follow-up visits. We used survival analysis to compare time to achieve the deﬁned 
goal (patients without diabetes: systolic blood pressure (SBP)  140, patients with 
diabetes: SBP  130) between the two groups controlling for confounders and clusters 
of patients. RESULTS: A total of 250 subjects were included in the study; half in the 
intervention group. Approximately 90% of the participants were African American 
and 60% were males. The baseline blood pressure levels were 149/88 mmHg and 
146/88 mmHg in the control and intervention group (p  0.25). After controlling 
baseline blood pressure, gender, race, age, diabetes, smoking and patient clusters, we 
found that patients in the intervention group reached goal at a rate 4.97 times (95% 
CI: 2.02–12.25) higher than the rate in the control group. However, higher baseline 
SBP (HR  0.96, 95% CI: 0.93–0.98), males (HR  0.54, 95% CI: 0.31–0.95) and 
smoking (HR  0.39, 95% CI: 0.20–0.77) were signiﬁcantly associated with longer 
time to achieve the goal. CONCLUSIONS: Patients who approached hypertension 
management with their peers were much more likely to achieve blood pressure control 
in a shorter time than patients in standard of care. These ﬁndings have implications 
for clinical and public health interventions.
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OBJECTIVES: In 2004 and 2005, Menzis, a Dutch health insurance, company stimu-
lated physicians in prescribing cheaper versions of statins and proton pump inhibitors 
by offering ﬁnancial incentives to physicians who could reach speciﬁc annual prescrib-
ing thresholds (preference policy). The objective of this research is to quantify the 
effect of the preference policy of Menzis on the utilization/demand of statins in the 
Northern part of The Netherlands. Furthermore, we test the hypothesis of a signiﬁcant 
difference in the increase of simvastatin starters between Menzis and the other insur-
ance companies potentially due to the preference policy. METHODS: Prescription 
data originating from the Northern The Netherlands on the amount of simvastatin 
starters and simvastatin market share were extracted from IADB.nl, an in-house pre-
scription database of the University of Groningen. State-space analysis was used in 
order to estimate the effect of the preference policy. The Kalman ﬁlter was applied on 
an intervention state space model, followed by diagnostic tests for the independence, 
homoscedasticity and normality of the standardized prediction errors. RESULTS: A 
sharp increase in the level as well as in the trend of the market share of simvastatin 
around the last trimester of 2004 was observed, corresponding to the time point when 
the preference policy was initiated. A steep increase was apparent also on both the 
amount of Menzis clients that started use of simvastatin, as well as on the market 
share of simvastatin among Menzis clients. The interventions had a signiﬁcant, 
decreasing effect on the cost of simvastatin treatment. CONCLUSIONS: The prefer-
ence policy resulted in an increase of prescribing for simvastatin, the cheaper statin 
alternative, which consequently resulted in a decrease in cholesterol lowering treat-
ment costs.
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OBJECTIVES: In 2006, US Medicare created a new drug beneﬁt (Part D) for older 
adults. Part D cut down the number of older adults lacking drug coverage and reduced 
out-of-pocket costs, yet little is known about its effect on treatment of speciﬁc condi-
tions. Given Medicare’s role in ﬁnancing 20% of US and 9% of global pharmaceutical 
expenditures it is important to evaluate its effects. We examined Part D’s effect on 
drug utilization for congestive heart failure (CHF), a condition with substantial mor-
bidity and mortality. METHODS: Quasi-experimental study using insurance claims 
data from 7201 older adults with CHF continuously enrolled in a Medicare plan in 
2004–07. Three intervention groups with either no or limited drug coverage in 2004–
05 (US$600 or US$1400 annual limits) who obtained Part D drug beneﬁts in 2006 
were compared with a group with generous pharmacy beneﬁts throughout 2004–07. 
We estimated Part D’s effect on CHF drug utilization and adherence, adjusting 
for differences in sociodemographic and health status measures. RESULTS: Part D 
was associated with a 37% (95% CI 31–43%) increase in CHF prescriptions ﬁlled by 
the group previously lacking coverage, and increases of 10% (95% CI 6–12) and 7% 
(95% CI 6–8%) in the groups with limited prior coverage, relative to comparison 
group. The group previously lacking coverage was more likely to be adherent to 
angiotensin-converting enzyme inhibitors (ratio of odds ratios 2.20, 95% CI 1.65–
2.88) and beta blockers (ratio of odds ratios 2.56, 95% CI 1.95–3.35) after Part D 
relative to comparison group. Groups with limited prior drug coverage experienced 
statistically signiﬁcant, if smaller, improvements in adherence. CONCLUSIONS: 
Medicare Part D was associated with signiﬁcant improvements in adherence to phar-
macotherapy for CHF, the magnitude of which varied with the level of prior drug 
coverage. These ﬁndings have implications for health systems contemplating drug 
coverage expansions.
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OBJECTIVES: Market concentration of products affects competition, and thus is a 
key concern of marketing ﬁrms, policy makers, and regulators. Angiotensin converting 
enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers(ARBs) are two 
classes of hypertensive drugs, competing for one of the largest and most proﬁtable 
pharmaceutical market in the US. However, little is known about how market con-
centration affects the consumption of these drugs. We sought to measure the concen-
tration of drugs in ACE inhibitors and ARBs and its association with their relative 
market share. METHODS: We used the State Drug Use Data from the Medicaid Drug 
Rebate Program that provides prescription drugs to 46 million low-income Americans. 
We linked the data with the WHO Collaborating Centre for Drug Statistics Methodol-
ogy to obtain Deﬁned Daily Dose (DDD) measurements for drug consumption for 
four large states, for a total of 16 quarters of continuous measurements between 2005 
and 2008. We used a Herﬁndahl-Hirschman Index (HHI) to measure the concentra-
tion in ACE inhibitors and ARBs, by DDD and reimbursements. We conducted mul-
tivariate GLS regression analysis by regressing the HHI on the relative market share 
of ACE inhibitors, adjusted for time trend, the interaction between the HHI and time 
trend, and random effects of states. RESULTS: During the 16 quarters between 2005 
and 2008, the mean concentration index for ACE Inhibitors was 339 (s.d. 71) by 
DDD, 442 (s.d. 148) by reimbursements, and for ARBs 887 (s.d. 277), 693 (s.d. 227) 
by DDD and reimbursements, respectively. The market share of ACE inhibitors was 
negatively associated with the concentration in ARBs (p  0.001, p  0.001), and 
marginally positively associated with the concentration in ACE inhibitors (p  0.05, 
p  0.09), by DDD and reimbursements, respectively. CONCLUSIONS: The relative 
market share of ACE inhibitors and ARBs is cross-linked with concentration of drugs 
within each of these two classes.
